Previous 10 | Next 10 |
Gainers: Obalon Therapeutics (OBLN) +438%.Caladrius Biosciences (CLBS) +121%.Adamis Pharmaceuticals (ADMP) +72%.Steel Connect (STCN) +54%.Titan Medical (TMDI) +52%.Tiziana Life Sciences (TLSA) +50%.Iterum Therapeutics (ITRM) +40%.Dare Bioscience (DARE) +33%.17 Education & T...
Caladrius Biosciences (CLBS) +120%.Aptorum Group (APM) +61% as Canada approves early-stage infection drug trial.Steel Connect (STCN) +54%.Dare Bioscience (DARE) +39%.ENDRA Life Sciences (NDRA) +36%.Lineage Cell Therapeutics (LCTX) +34%.Inuvo (INUV) +33%.eMagin Corporation (EMAN) +28...
Gainers: Aclaris Therapeutics (ACRS) +184%.Gritstone Oncology (GRTS) +111%.Gevo (GEVO) +76%.Senseonics (SENS) +72%.TransEnterix (TRXC) +62%.Dare Bioscience (DARE) +57%.ENDRA Life Sciences (NDRA) +41%.Pennsylvania Real Estate Investment Trust (PEI) +41%.Tenax Therapeutics (TENX)...
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIO...
Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...
Daré Bioscience ([[DARE]] -10.0%) reports topline data from Phase 3 DARE-BVFREE trial evaluating DARE-BV1 for the treatment of bacterial vaginosis. The trial met its primary endpoint demonstrating that a single administration of DARE-BV1 was superior to placebo, though reported...
Eastman Kodak (KODK) +76%. as DFC says no laws were broken.Greenland Technologies Holding (GTEC) +60% on launching 'electric industrial vehicle market' divisionObalon Therapeutics (OBLN) +52%.Oncternal Therapeutics (ONCT) +27% on presentation of interim phase 1/2 data...
DARE-BV1 met the primary endpoint of the study and all pre-specified secondary efficacy endpoints; demonstrated significantly greater clinical cure rates compared to placebo DARE-BV1 has Fast Track and QIDP designatio...
Daré Bioscience, Inc. (DARE) Q3 2020 Results Earnings Conference Call November 12, 2020, 04:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Jason Kolb...
Dare Bioscience (DARE): Q3 GAAP EPS of -$0.24 misses by $0.06.Cash and cash equivalents of ~$5.4M.Press Release For further details see: Dare Bioscience EPS misses by $0.06
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...